Sanofi's Annual General Meeting on April 29, 2026, appointed Belén Garijo as the new CEO effective May 1, 2026. Garijo brings extensive experience in healthcare leadership and R&D, previously leading Merck's healthcare division and holding senior roles at Sanofi. The company aims to leverage her expertise to enhance execution discipline, capital allocation, and sustainable performance. The meeting also approved a dividend of €4.12 per share and welcomed new board members, emphasizing diversity and digital expertise.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
